258 related articles for article (PubMed ID: 26487696)
41. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
42. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
43. The association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese population.
Yuan X; Meng Y; Li P; Ge N; Kong F; Yang L; Björkholm M; Zhao S; Xu D
Oncotarget; 2016 May; 7(22):31972-9. PubMed ID: 26934125
[TBL] [Abstract][Full Text] [Related]
44. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
[TBL] [Abstract][Full Text] [Related]
45. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M
Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014
[TBL] [Abstract][Full Text] [Related]
46. Association between the rs2736100 polymorphisms of telomerase reverse transcriptase gene and digestive cancers: A meta-analysis.
Song H; Han M; Li K; Zhao Y; Xu C; Lei X
J Cancer Res Ther; 2021 Nov; 17(5):1202-1208. PubMed ID: 34850768
[TBL] [Abstract][Full Text] [Related]
47. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
[TBL] [Abstract][Full Text] [Related]
48. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
49. Molecular characterization of chronic myeloproliferative neoplasias in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
[TBL] [Abstract][Full Text] [Related]
50. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
51. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
52. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
53. Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.
Ge M; Shi M; An C; Yang W; Nie X; Zhang J; Lv Z; Li J; Zhou L; Du Z; Yang M
Sci Rep; 2016 May; 6():26037. PubMed ID: 27185198
[TBL] [Abstract][Full Text] [Related]
54. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
55. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
56. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.
Pardanani A; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Hanson CA; Tefferi A
Leukemia; 2010 Jan; 24(1):110-4. PubMed ID: 19847198
[TBL] [Abstract][Full Text] [Related]
57. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
58. The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Both A; Krauter J; Damm F; Thol F; Göhring G; Heuser M; Ottmann O; Lübbert M; Wattad M; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Brugger W; Schlegelberger B; Heil G; Ganser A; Wagner K
Ann Hematol; 2017 Jun; 96(6):895-904. PubMed ID: 28331964
[TBL] [Abstract][Full Text] [Related]
59. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
Goodyer M; Langabeer SE; Haslam K; Murphy K
Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
[No Abstract] [Full Text] [Related]
60. The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms.
Daglar-Aday A; Akadam-Teker B; Yonal-Hindilerden I; Dermenci H; Sahin E; Hindilerden F; Yilmaz-Aydogan H; Ozturk O; Yavuz AS
Mol Biol Rep; 2020 Oct; 47(10):7413-7420. PubMed ID: 32918123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
